EAU 2023 | CDH1-mutated clinically advanced urothelial bladder cancer: real-world clinical outcome study
Philippe Spiess, MD, Moffitt Cancer Center, Tampa, FL, provides an overview of a genomic landscape and real-world clinical outcome study of CDH1-mutated clinically advanced urothelial bladder cancer (UBC). CDH1 mutated UBCs are characterized by plasmacytoid histology and are associated with an aggressive clinical course at the time of diagnosis. Using the National Cancer Database and the Flatiron Heath-Foundation Medicine Urothelial Clinico-Genomic Database, the study showed CDH1 mutation predicts resistance to immune checkpoint inhibitor-based treatments but does not impact responsiveness to chemotherapy. This interview took place at the EAU congress in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
